Skip to content

Effect of Endometrial Perfusion of Platelet Rich Plasma (PRP) in IVF patients

Effect of Endometrial Perfusion of Platelet Rich Plasma (PRP) on success of Frozen Embryo Transfer (FET) - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076262
Enrollment
100
Registered
2024-11-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 1- Obstetrics

Interventions

Intervention1: Platelet rich Plasma: Patients with PRP intrauterine perfusion on endometrial transformation day will be correlated with Frozen embryo transfer women who received intrauterine perfusion

Sponsors

Datta Meghe Institute Of Higher Education And Research,Sawangi Meghe, Wardha India 442001
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Women aged 18- 45 yrs 2.The lack of contraindications for PRP treatment ( Hb-less than 10gm%, low platelet count, sickle cell disease, chronic neutropenia, known past or present malignancy, renal insufficiency, upper respiratory infection, pneumonia anf congenital fructose intolerance) 3.Women with a normal transvaginal ultrasound and no evidence of a clinically significant abnormality in the uterus or adnexa. 4.Negative CBNAAT, AFB staining and TBPCR for genital tuberculosis.

Exclusion criteria

Exclusion criteria: 1.Patients with BMI greater than 30 kg/m2 2.Positive history of intrauterine synechiae, repeated currettage, endometrial injury 3.Distorted endometrial cavity because of recurrent adhesions, submucosal fibroids, endometrial polyps, severe endometriosis, adenomyosis, pelvic cancer and uterine anomalies. 4.Chromosomal abnormalities in couples. 5.Patients with abnormal liver and kidney function, abnormal thyroid function, immune disorders or hematological disorders.

Design outcomes

Primary

MeasureTime frame
Rate of positive Beta HCG , positive UPT, appearance of gestational sac and cardiac activity on USGTimepoint: Assessment will be done after 4 weeks

Secondary

MeasureTime frame
NILTimepoint: NA

Countries

India

Contacts

Public ContactKhushboo Shah

Datta Meghe institute of higher education and research

deepti_shrivastava69@yahoo.com9860817801

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026